索拉非尼联合部分性脾动脉栓塞术治疗巴塞罗那临床 C 期肝癌合并脾功能亢进：病例系列研究。
Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series.
机构信息
Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), Chongqing University Cancer Hospital, Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China.
出版信息
J Int Med Res. 2021 Jun;49(6):3000605211023351. doi: 10.1177/03000605211023351.
BACKGROUND
Sorafenib is mainly used to treat patients with hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stage C, many of whom also have severe cirrhosis. However, hypersplenism and digestive tract hemorrhage are common complications of cirrhosis, which increase the risk and difficulty of treatment.
METHODS
Nineteen patients with HCC BCLC stage C with hypersplenism were treated with sorafenib plus partial splenic embolism at Chongqing University Cancer Hospital, Chongqing, China, between January 2015 and June 2018. We analyzed the therapeutic effect and clinical safety of this treatment in these patients.
RESULT
Hypersplenism was rectified in all patients. The incidence rates of hemorrhage and myelosuppression were 0%, and the mean survival time was 11.2 months.
CONCLUSION
Sorafenib plus partial splenic embolism could relieve hypersplenism and prolong survival in patients with BCLC stage C HCC.
背景
索拉非尼主要用于治疗巴塞罗那临床肝癌（BCLC）分期 C 的肝细胞癌（HCC）患者，其中许多患者还患有严重的肝硬化。然而，肝硬化常见的并发症包括脾功能亢进和消化道出血，这增加了治疗的风险和难度。
方法
中国重庆大学附属肿瘤医院于 2015 年 1 月至 2018 年 6 月期间对 19 例伴有脾功能亢进的 HCC BCLC 分期 C 患者采用索拉非尼联合部分性脾动脉栓塞术进行治疗。我们分析了该治疗方案在这些患者中的治疗效果和临床安全性。
结果
所有患者的脾功能亢进均得到纠正。出血和骨髓抑制的发生率均为 0%，平均生存时间为 11.2 个月。
结论
索拉非尼联合部分性脾动脉栓塞术可缓解 BCLC 分期 C 的 HCC 患者的脾功能亢进并延长其生存时间。
Zotero 插件